CHEK vs. XCUR, SRGA, ICU, AEMD, BLCM, PYPD, TENX, RSLS, GLMD, and ADIL
Should you be buying Check-Cap stock or one of its competitors? The main competitors of Check-Cap include Exicure (XCUR), Surgalign (SRGA), SeaStar Medical (ICU), Aethlon Medical (AEMD), Bellicum Pharmaceuticals (BLCM), PolyPid (PYPD), Tenax Therapeutics (TENX), ReShape Lifesciences (RSLS), Galmed Pharmaceuticals (GLMD), and Adial Pharmaceuticals (ADIL). These companies are all part of the "medical" sector.
Check-Cap vs.
Check-Cap (NASDAQ:CHEK) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.
Check-Cap has a net margin of 0.00% compared to Exicure's net margin of -8.96%. Check-Cap's return on equity of -41.04% beat Exicure's return on equity.
Check-Cap received 361 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 69.94% of users gave Check-Cap an outperform vote while only 47.37% of users gave Exicure an outperform vote.
17.6% of Check-Cap shares are owned by institutional investors. Comparatively, 39.0% of Exicure shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by company insiders. Comparatively, 3.9% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Exicure has higher revenue and earnings than Check-Cap. Exicure is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.
In the previous week, Check-Cap had 2 more articles in the media than Exicure. MarketBeat recorded 2 mentions for Check-Cap and 0 mentions for Exicure. Check-Cap's average media sentiment score of 0.00 equaled Exicure's average media sentiment score.
Check-Cap presently has a consensus price target of $7.00, suggesting a potential upside of 293.26%. Given Check-Cap's higher possible upside, equities analysts clearly believe Check-Cap is more favorable than Exicure.
Summary
Check-Cap beats Exicure on 8 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CHEK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Check-Cap Competitors List
Related Companies and Tools